Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient demographic characteristics (intention-to-treat population)

From: A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

  PF-06438179/GP1111
(n = 324)
Infliximab-EU
(n = 326)
All patients
(N = 650)
Gender, n (%)
 Female 258 (79.4) 264 (81.0) 522 (80.3)
 Male 66 (20.4) 62 (19.0) 128 (19.7)
Age, mean (SD), years 52.8 (13.3) 52.8 (12.9) 52.8 (13.1)
Weight, mean (SD), kg 73.3 (19.8) 74.2 (20.0) 73.8 (19.9)
Body mass index, mean (SD), kg/m2 27.2 (6.4) 27.7 (7.0) 27.4 (6.7)
Race, n (%)
 White 257 (79.3) 247 (75.8) 504 (77.5)
 Black 5 (1.5) 9 (2.8) 14 (2.2)
 Asian 46 (14.2) 45 (13.8) 91 (14.0)
 Other 15 (4.6) 25 (7.7) 40 (6.2)
 Unspecified 1 (0.3) 0 1 (0.2)
Geographic region, n (%)
 North American and Western Europe 50 (15.4) 51 (15.6) 101 (15.5)
 Japan 24 (7.4) 23 (7.1) 47 (7.2)
 South Korea 4 (1.2) 5 (1.5) 9 (1.4)
 Latin America 22 (6.8) 22 (6.7) 44 (6.8)
 Rest of the world 224 (69.1) 225 (69.0) 449 (69.1)
  1. Infliximab-EU Infliximab sourced from the European Union